Slide 1: Investor Presentation, July 2019
Investor Presentation, July 2019
Slide 2: Disclaimer ‘Forward-Looking' Statements
Disclaimer ‘Forward-Looking' Statements Summary of information: This presentation contains general and background information about Mach7 Technologies Limited (“M7T”) activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the informa
Slide 3: Who is Mach7 (ASX:M7T)?
Who is Mach7 (ASX:M7T)? Enterprise Imaging Software provider to hospitals and clinics Global imaging market >US$3BN Delivery: On-premise, cloud solutions Growing global customer base: USA, UK, Qatar, South East Asia … Two revenue models: SaaS & capital sales Employing ~40 staff USA HQ Bu
Slide 4: Mach7 Technologies (M7T)
Mach7 Technologies (M7T) FINANCIAL INFORMATION ($A) MAJOR SHAREHOLDERS Share price $0.76 JM Financial Group 18.1% Number of shares (m) 147.8m BV Healthcare 7.9% Market Capitalisation $112.3m Australian Ethical 4.7% Cash (30-Jun-19) $2.3m Ravi Krishnan (founder) 3.8% Debt (30-Jun-19) $0.6m Enterprise
Slide 5: Business Highlights
Business Highlights New CEO Restructured Board of Directors VP Sales and VP Service hired to strengthen US team VP Operations hired to strengthen ASPAC team Major customer implementations on track 4 x go-lives planned through to 31 Dec 2019 Robust sales pipeline Largest sale in US an
Slide 6: Mach7 Evolution – Company & Product
Mach7 Evolution – Company & Product 2007 2010 2012 2016 2017 Mach7 First Pilots First Listed M7T:ASX Expanded Product Founded Deployed Commercial Offerings Wins Specialty Applications: v8 Enterprise Imaging Platform: v11 Data Services Platform: v12 Vendor Neutral Archive Management Studio Clinical S
Slide 7: What is Enterprise Imaging
What is Enterprise Imaging Drivers of Enterprise Imaging Enterprise imaging Electronic Health Record (EHR) as a precursor • The Mach7 Platform provides an Enterprise- wide imaging solution to Enterprise Imaging Hospital Consolidation Simplify Supply Chains Sharing, outsourcing & Need for scalable ca
Slide 8: Mach7 Enterprise Imaging Product Strategy
Mach7 Enterprise Imaging Product Strategy Referring Physician Radiologist Vendor Neutral Archive Core Capability is providing Mach7 sells a Picture Archive and (VNA) is the cornerstone Enterprise Imaging (EI) Communications System (PACS) of the EI market solutions for healthcare with its partn
Slide 9: Addressable Global Imaging Market
Addressable Global Imaging Market Mach7 Addressable Market* 3,500 • Enterprise Imaging Market (EI) 3,000 $520M* 2018 – with forecast growth 2,500 ~30%* p/a for next two years • EI market is fastest growing market 2,000 • Standalone departmental PACS $2BN 1,500 2018* however market is shrinking in fa
Slide 10: “Mach7 Management Studio” - VNA
“Mach7 Management Studio” - VNA Why customers buy a PACS VNA: • Providing additional Many healthcare providers Mach7’s Core storage are moving toward a multi- Product is VNA • Long-term disaster clinical Management Platform “Management Studio” recovery for all content across their • Connecting dispa
Slide 11: “Mach7 Diagnostic Studio” - PACS Solution
“Mach7 Diagnostic Studio” - PACS Solution An integration platform first → enables speed, performance, flexibility True zero-footprint (ZFP) viewer → NO client-side software One ZFP platform for all users and devices; browser and device agnostic Does NOT have 100% streaming like all other sol
Slide 12: Mach7 Competitive Advantages
Mach7 Competitive Advantages Interoperability across the enterprise (connecting all systems, across all ‘ologies’) Customer controls their Attractive own data – easy Price Point user interface and rules engine Very Little Hardware (Lowers cost and Ease of Install accelerates install) 12
Slide 13: Recent Wins – CY19
Recent Wins – CY19 $5.1M / 5 yrs. $2.1M / 5 yrs. $760k $365k / 5 yrs. $43k $57k $25k Mississippi State Loyola University Children’s Advocate Aurora University Veterinary Health System Alabama Health (Clinical Portal) Maine Health (Migration) Sampson Regional Sentara Healthcare (Cardiology viewer Med
Slide 14: Hospital Authority of Hong Kong
Hospital Authority of Hong Kong • Deal value HK$81 Million (~ A$15M) / 5 years • Enterprise Imaging and Viewer for entire Hong Kong territory • The Hospital Authority manages 43 public hospitals and institutions, 48 specialist outpatient clinics and 73 general outpatient clinics. • Customer Objectiv
Slide 15: Sentara Healthcare
Sentara Healthcare • Enterprise Imaging, Migration & PACS Modernisation Projects • Mach7 VNA and 20 million study migration underway. • Recent PACS modernization contract won $2.1M over 5 years + volume expansion. 100% GM. • Customer Objectives • Reduce complexities and costs related to system integ
Slide 16: Advocate Aurora Health
Advocate Aurora Health • Mach7 Platform & Migration • Mach7 Platform to be health-network-wide • ~3.5 Petabytes of archived data to migrate • Contract value $5.1M over 5 years • Customer Objectives • Enable scalable and interoperable platform to meet their business goals → goal to double current siz
Slide 17: Revenue Models
Revenue Models Capital Sales Subscription Sales Revenue Component Priced Revenue Recognised Priced Revenue Recognised Upfront when license is Software license fees By Procedure Volume By Procedure Volume Monthly* provided Annual support % of License Monthly* By Procedure Volume Monthly* As services
Slide 18: Revenues
Revenues Annual Recurring Revenue (ARR) A$ 9,000,000 • Total Contracted ARR $8.5M - 72% 8,000,000 growth (today v ’18) 7,000,000 • ARR 36% growth (FY19 est. vs ‘18) 6,000,000 5,000,000 • FY19 expected to exceed FY2018 4,000,000 revenues of $8.6M 3,000,000 2,000,000 1,000,000 0 2016 2017 2018 2019* R
Slide 19: Growth Strategy
Growth Strategy Focus on core products: enterprise imaging market space Focus on allocating resources towards commercial side of the business: sales, marketing, product management Focus on major markets where we already have an install base and good brand recognition: USA, Asia, Qatar, Saudi Arabia
Slide 20: What’s next? Next six months…
What’s next? Next six months… Continued progress to cashflow break-even for 12 months ending February 2020 Contract wins – US & Asia Expand partnerships Re-investing some cost savings into operational roles 20
Slide 21: Mach7 Board and Leadership Team
Mach7 Board and Leadership Team MANAGEMENT Mike Jenni Pilcher David Eliot Siegel, MD CFO, Company Lampron BOARD Chambers NON-EXECUTIVE Secretary NON-EXECUTIVE MD & CEO DIRECTOR CHAIRMAN Executive experience in ASX- Thought leader in the world of 20+ years experience in listed healthcare compan